의약품 수탁제조 시장 : 서비스별, 최종사용자별 - 세계 예측(2025-2030년)

The Pharmaceutical Contract Manufacturing Market was valued at USD 114.07 billion in 2023, expected to reach USD 123.64 billion in 2024, and is projected to grow at a CAGR of 8.46%, to USD 201.46 billion by 2030.

The pharmaceutical contract manufacturing market involves outsourcing manufacturing services, including drug production and packaging, by pharmaceutical companies to specialized third-party organizations. This sector is vital due to the pharmaceutical industry's growing need for scalable production capabilities, cost efficiency, and expertise enhancement. Contract manufacturing primarily finds application in biologics, active pharmaceutical ingredients (APIs), solid and semi-solid dosage forms, and injectables, addressing the production needs across multiple end-users such as biopharmaceutical companies, generic drug manufacturers, and small-scale biotech firms. Market growth is driven by the rising demand for generic drugs, the increasing complexity of manufacturing biologics, stringent regulatory requirements, and the emphasis on cost containment within the pharmaceutical industry. Emerging markets and continuous R&D investment provide potential growth opportunities, where developing strong partnerships and focusing on quality compliance can be decisive. There's a growing trend towards strategic partnerships and mergers, enhancing capabilities to capture market share. However, challenges include intense competition, regulatory compliance complexities, and the risk of intellectual property theft or data breaches. Other limitations involve the high cost of setting up advanced manufacturing facilities and maintaining technological adaptability. Innovation in areas like continuous manufacturing, personalized medicine production, and advanced packaging solutions is critical. These innovations not only ensure higher efficiency but also better address client-specific requirements. Furthermore, integrating artificial intelligence and machine learning can streamline production processes and improve supply chain management. For business growth, it's essential to focus on building robust global supply chain networks and advancing digital transformation to remain competitive. The market's nature is collaborative, with a growing emphasis on quality assurance and client transparency to succeed. Such efforts are crucial in responding effectively to the dynamic demands and growing complexities of pharmaceutical production globally.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Pharmaceutical Contract Manufacturing Market

The Pharmaceutical Contract Manufacturing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising Demand for Generics and Biological Therapies
  • Increasing Investments in Pharmaceutical R&D and Manufacturing
  • Increasing Number of CMOs and Rising Investments in Advanced Manufacturing Technologies
• Market Restraints
  • Introduction of Serialization Standards
• Market Opportunities
  • Increasing Focus on Specialty Drugs and Attractive Nuclear Medicine Sector
  • Growing Demand for Cell and Gene Therapies for Targeted Treatment
• Market Challenges
  • Changing Trade Policies Between Countries

Porter's Five Forces: A Strategic Tool for Navigating the Pharmaceutical Contract Manufacturing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Pharmaceutical Contract Manufacturing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Pharmaceutical Contract Manufacturing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Pharmaceutical Contract Manufacturing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Pharmaceutical Contract Manufacturing Market

A detailed market share analysis in the Pharmaceutical Contract Manufacturing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Pharmaceutical Contract Manufacturing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Pharmaceutical Contract Manufacturing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Pharmaceutical Contract Manufacturing Market

A strategic analysis of the Pharmaceutical Contract Manufacturing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Pharmaceutical Contract Manufacturing Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Inc., Aenova Group GmbH, Almac Group, Amgen Inc., Baxter International Inc., Biozoc Inc., Boehringer Ingelheim International GmbH, Cambrex Corporation, Catalent, Inc., Curia Global, Inc., Danaher Corporation, Dr. Reddy's Laboratories Ltd., Elkos Group, Evonik Industries AG, Famar Group, Fareva Group, Jubilant Pharma Limited, Kryptochem Medicament Pvt. Ltd., Lonza Group, Midas Pharma GmbH, Mitsubishi Tanabe Pharma Corporation, Nipro Group, Novartis AG, Pfizer Inc., Pidolma Healthcare, PYRAMID Laboratories, Inc., Recipharm AB, Serum Institute of India Ltd., Siegfried Holding AG, Sycon Healthcare, Thermo Fisher Scientific Inc., and Vetter Pharma-Fertigung GmbH & Co. KG.

Market Segmentation & Coverage

This research report categorizes the Pharmaceutical Contract Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Service, market is studied across Biologics Manufacturing Services, Drug Development Services, Pharmaceutical Manufacturing Services, and Secondary Packaging Services. The Biologics Manufacturing Services is further studied across Biologics API Manufacturing Services and Biologics FDF Manufacturing Services. The Pharmaceutical Manufacturing Services is further studied across Pharmaceutical API Manufacturing and Pharmaceutical FDF Manufacturing. The Pharmaceutical API Manufacturing is further studied across Capsule Manufacturing Services, Oral Liquid Manufacturing Services, Parenteral/Injectable Manufacturing Services, and Tablet Manufacturing Services.
• Based on End-User, market is studied across Big Pharma, Generic Pharmaceutical Companies, and Small & Mid-Size Pharma.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising Demand for Generics and Biological Therapies
    • 5.1.1.2. Increasing Investments in Pharmaceutical R&D and Manufacturing
    • 5.1.1.3. Increasing Number of CMOs and Rising Investments in Advanced Manufacturing Technologies
  • 5.1.2. Restraints
    • 5.1.2.1. Introduction of Serialization Standards
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing Focus on Specialty Drugs and Attractive Nuclear Medicine Sector
    • 5.1.3.2. Growing Demand for Cell and Gene Therapies for Targeted Treatment
  • 5.1.4. Challenges
    • 5.1.4.1. Changing Trade Policies Between Countries
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Pharmaceutical Contract Manufacturing Market, by Service

• 6.1. Introduction
• 6.2. Biologics Manufacturing Services
  • 6.2.1. Biologics API Manufacturing Services
  • 6.2.2. Biologics FDF Manufacturing Services
• 6.3. Drug Development Services
• 6.4. Pharmaceutical Manufacturing Services
  • 6.4.1. Pharmaceutical API Manufacturing
    • 6.4.1.1. Capsule Manufacturing Services
    • 6.4.1.2. Oral Liquid Manufacturing Services
    • 6.4.1.3. Parenteral/Injectable Manufacturing Services
    • 6.4.1.4. Tablet Manufacturing Services
  • 6.4.2. Pharmaceutical FDF Manufacturing
• 6.5. Secondary Packaging Services

7. Pharmaceutical Contract Manufacturing Market, by End-User

• 7.1. Introduction
• 7.2. Big Pharma
• 7.3. Generic Pharmaceutical Companies
• 7.4. Small & Mid-Size Pharma

8. Americas Pharmaceutical Contract Manufacturing Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Pharmaceutical Contract Manufacturing Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Pharmaceutical Contract Manufacturing Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
  • 11.3.1. Maiva Pharma secures USD 119 million investment to expand manufacturing with new Hosur facility
  • 11.3.2. Kuhne Holding AG acquires Aenova Group from BC Partners
  • 11.3.3. Tonix Pharmaceuticals partners with Almac for dual-source commercial production of Tonmya
  • 11.3.4. Advent International merges Cohance Lifescience with Suven Pharma
  • 11.3.5. Aurobindo Pharma partners with Merck Sharp and Dohme to enter biologics contract manufacturing market
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie, Inc.
• 2. Aenova Group GmbH
• 3. Almac Group
• 4. Amgen Inc.
• 5. Baxter International Inc.
• 6. Biozoc Inc.
• 7. Boehringer Ingelheim International GmbH
• 8. Cambrex Corporation
• 9. Catalent, Inc.
• 10. Curia Global, Inc.
• 11. Danaher Corporation
• 12. Dr. Reddy's Laboratories Ltd.
• 13. Elkos Group
• 14. Evonik Industries AG
• 15. Famar Group
• 16. Fareva Group
• 17. Jubilant Pharma Limited
• 18. Kryptochem Medicament Pvt. Ltd.
• 19. Lonza Group
• 20. Midas Pharma GmbH
• 21. Mitsubishi Tanabe Pharma Corporation
• 22. Nipro Group
• 23. Novartis AG
• 24. Pfizer Inc.
• 25. Pidolma Healthcare
• 26. PYRAMID Laboratories, Inc.
• 27. Recipharm AB
• 28. Serum Institute of India Ltd.
• 29. Siegfried Holding AG
• 30. Sycon Healthcare
• 31. Thermo Fisher Scientific Inc.
• 32. Vetter Pharma-Fertigung GmbH & Co. KG